JAMES PATRINELY to Melanoma
This is a "connection" page, showing publications JAMES PATRINELY has written about Melanoma.
Connection Strength
2.478
-
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. JAMA Oncol. 2021 05 01; 7(5):744-748.
Score: 0.456
-
A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. Oncoimmunology. 2021 02 08; 10(1):1875639.
Score: 0.449
-
The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. BioDrugs. 2020 Aug; 34(4):495-503.
Score: 0.433
-
Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma. Cancer. 2020 08 01; 126(15):3448-3455.
Score: 0.427
-
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma. JAMA Netw Open. 2023 08 01; 6(8):e2327145.
Score: 0.133
-
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. Eur J Cancer. 2022 11; 176:121-132.
Score: 0.126
-
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply. Lancet Oncol. 2021 08; 22(8):e343-e344.
Score: 0.116
-
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021 06; 22(6):836-847.
Score: 0.114
-
Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. J Immunother Cancer. 2021 05; 9(5).
Score: 0.114
-
Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma. Clin Cancer Res. 2021 01 01; 27(1):131-140.
Score: 0.110